The CDC has released the report for the upcoming 2018-19 flu season. The updates are based on the recommendations of the ACIP Influenza Work Group that meets throughout the year to ensure guidance is as up to date as possible regarding the use of seasonal influenza vaccines. The new guidance addresses several issues, including the vaccine virus composition. The CDC guidance states
Routine annual influenza vaccination of all persons aged ≥6 months without contraindications continues to be recommended. No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended, and appropriate product is available.
CDC recommends that people get a flu vaccine by the end of October. Getting vaccinated later, however, can still be beneficial and vaccination should continue to be offered throughout flu season, even into January or later.
Children who need two doses of vaccine to be protected should start the vaccination process sooner, because the two doses must be given at least four weeks apart.
Note: The recommendation for vaccination to be completed by end of October 2019 is also supported by the AAP
JAMA (November, 2018) has reprinted key tables from the Medical Letter on Drugs and Therapeutics that provide information on vaccine availability, formulations and recommended ages (see ‘Learn More – Primary Sources’ below)
Vaccination against seasonal influenza is recommended for all persons aged 6 months or older, including pregnant women.
Recombinant, high-dose, and adjuvanted vaccines elicit greater antibody responses than standard-dose unadjuvanted vaccines among persons aged 65 years or older, and the high-dose and recombinant vaccines have been shown in randomized clinical trials to be more effective among older patients in preventing laboratory-confirmed influenza.
Live Attenuated Influenza Vaccine (LAIV4) Now Recommended
Note: ACIP recommends that LAIV4 not be used for immunocompromised persons or during pregnancy
Note: A previous severe allergic reaction to influenza vaccine, regardless of the component suspected of being responsible for the reaction, is a contraindication to future receipt of the vaccine
Important Regulatory Changes
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.